RxDoctor Payments Data

Manjaree Daw, MD

Internal Medicine · Port St Lucie, FLNPI 1972587038

Payments from drug & device makers

$791in general payments, 2019–2025

Across 24 payments — averaging $32.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$181
  • Cardiovascular Systems Inc.$171
  • Edwards Lifesciences$130
  • Boehringer Ingelheim$119
  • Johnson & Johnson$105
  • Novo Nordisk$42
  • plus $43 from 2 others

What the payments were for

  • Food & beverage$791100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$791 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$85,892
Medicare patients
271
Services billed
1,122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide33$32,032
JanuviaSitagliptin Phosphate21$20,509
EliquisApixaban11$14,599
Atorvastatin Calcium131$1,214
Rosuvastatin Calcium117$1,036
Pregabalin14$750
Duloxetine Hcl18$742
Tamsulosin Hcl33$738
Nano 2nd Gen Pen NeedlePen Needle, Diabetic12$720
Levothyroxine Sodium82$719
Pantoprazole Sodium46$702
Metoprolol Succinate39$687
Montelukast Sodium44$674
Albuterol Sulfate HfaAlbuterol Sulfate21$671
Losartan Potassium64$669

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$42$32,03233 claims
MerckJanuvia$29$20,50921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Port St Lucie

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →